- Home
- DSGN vs SABR Comparison
DSGN vs SABR Comparison
Compare DSGN & SABR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DSGN | SABR |
|---|---|---|
| Founded | 2017 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Programming Data Processing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 853.8M | 811.2M |
| IPO Year | 2021 | 2014 |
Fundamental Metrics
Financial Performance| Metric | DSGN | SABR |
|---|---|---|
| Price | $11.68 | $1.91 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 8 | 6 |
| Target Price | ★ $21.71 | $2.13 |
| AVG Volume (30 Days) | 636.2K | ★ 5.5M |
| Earning Date | 11-04-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 283.56 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $3,866,956,000.00 |
| Revenue This Year | N/A | $4.45 |
| Revenue Next Year | N/A | $4.13 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 7.46 |
| 52 Week Low | $5.28 | $0.81 |
| 52 Week High | $17.25 | $2.50 |
Technical Indicators
Market Signals| Indicator | DSGN | SABR |
|---|---|---|
| Relative Strength Index (RSI) | 34.55 | 37.00 |
| Support Level | $9.78 | $1.70 |
| Resistance Level | $11.88 | $1.99 |
| Average True Range (ATR) | 0.65 | 0.11 |
| MACD | -0.06 | -0.04 |
| Stochastic Oscillator | 6.10 | 0.83 |
Price Performance
Historical ComparisonAbout DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.
About SABR Sabre Corporation
Sabre holds the number-two air booking volume share in the global distribution system industry. The marketplace segment represented 80% of total 2025 revenue and airline technology solutions 20% of revenue. The company sold its growing hotel IT solutions division to TPG in 2025 for $960 million in net proceeds. Transaction fees, which are mostly tied to volume and not price, account for the bulk of sales and profits.